Stock Events

Stock Events

Oramed Pharmaceuticals 

€3.99
65
-€0.09-2.21% Friday 19:55

Statistics

Day High
4.1
Day Low
3.99
52W High
4.62
52W Low
1.842
Volume
5,000
Avg. Volume
-
Mkt Cap
165.77M
P/E Ratio
-
Dividend Yield
5.28%
Dividend
0.21

Upcoming

Dividends

5.28%Dividend Yield
Jan 26
€0.21
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

16NovExpected
Q1 2026
Q2 2026
Next
0.37
1.04
1.72
2.39
Expected EPS
0.370617
Actual EPS
N/A

Financials

2,919.5%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.85MRevenue
53.97MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OJU1.STU. It's not an investment recommendation.
Apple
18
AAPL
Microsoft
17
MSFT
NVIDIA
16
NVDA
Amazon
12
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap205.97B
Novo Nordisk is a leading global healthcare company that develops diabetes care products, directly competing with Oramed's oral insulin capsule.
Mannkind
MNKD
Mkt Cap1.31B
MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for diabetes, such as Afrezza, competing in the diabetes management space.
Sanofi
SNY
Mkt Cap106.01B
Sanofi is a multinational pharmaceutical company that offers a range of diabetes solutions, including insulin products, competing in the same therapeutic area as Oramed.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company is a global healthcare leader that develops a wide range of pharmaceutical products, including treatments for diabetes, directly competing with Oramed's products.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global, science-led biopharmaceutical business that has a significant portfolio of diabetes treatments, competing in the same market as Oramed.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol-Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines, including for diabetes, which puts it in competition with Oramed.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. offers a broad range of diabetes treatments, including oral medications, directly competing with Oramed's oral insulin product.
Tandem Diabetes Care
TNDM
Mkt Cap1.38B
Tandem Diabetes Care, Inc. designs, develops, and commercializes products for people with insulin-dependent diabetes, competing in the broader diabetes care market.
Insulet
PODD
Mkt Cap10.23B
Insulet Corporation is engaged in the development, manufacture, and sale of its Omnipod Insulin Management System, a competitor in the insulin delivery space.
Dexcom
DXCM
Mkt Cap33.17B
DexCom, Inc. specializes in continuous glucose monitoring (CGM) systems for diabetes management, indirectly competing by offering alternative diabetes management solutions.

About

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Show more...
CEO
Nadav Kidron
Employees
13
Country
United States
ISIN
US68403P2039
WKN
000A1CTNU

Listings

TA
IL
ORMP.TA
STU
DE
OJU1.STU
MU
DE
OJU1.MU
XNAS
US
ORMP

0 Comments

Share your thoughts

FAQ

What is Oramed Pharmaceuticals stock price today?▼
The current price of OJU1.STU is €3.99 EUR — it has decreased by -2.21% in the past 24 hours. Watch Oramed Pharmaceuticals stock price performance more closely on the chart.
What is Oramed Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Oramed Pharmaceuticals stocks are traded under the ticker OJU1.STU.
Is Oramed Pharmaceuticals stock price growing?▼
OJU1.STU stock has fallen by -6.89% compared to the previous week, the month change is a +5.56% rise, over the last year Oramed Pharmaceuticals has showed a +95.15% increase.
What is Oramed Pharmaceuticals market cap?▼
Today Oramed Pharmaceuticals has the market capitalization of 165.77M
When is the next Oramed Pharmaceuticals earnings date?▼
Oramed Pharmaceuticals is going to release the next earnings report on November 16, 2026.
What were Oramed Pharmaceuticals earnings last quarter?▼
OJU1.STU earnings for the last quarter are 2.39 EUR per share, whereas the estimation was 0.37 EUR resulting in a +541.86% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Oramed Pharmaceuticals revenue for the last year?▼
Oramed Pharmaceuticals revenue for the last year amounts to 1.85M EUR.
What is Oramed Pharmaceuticals net income for the last year?▼
OJU1.STU net income for the last year is 53.97M EUR.
Does Oramed Pharmaceuticals pay dividends?▼
Yes, OJU1.STU dividends are paid annual. The last dividend per share was 0.21 . As of today, Dividend Yield (FWD)% is 5.28%.
How many employees does Oramed Pharmaceuticals have?▼
As of September 13, 2026, the company has 13 employees.
In which sector is Oramed Pharmaceuticals located?▼
Oramed Pharmaceuticals operates in the Health & Wellness sector.
When did Oramed Pharmaceuticals complete a stock split?▼
The last stock split for Oramed Pharmaceuticals was on January 23, 2013 with a ratio of 1:12.
Where is Oramed Pharmaceuticals headquartered?▼
Oramed Pharmaceuticals is headquartered in NEW YORK, United States.